ACADIA Pharmaceuticals Inc ACAD:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 02/26/21 EST
48.01quote price arrow down-0.96 (-1.96%)
Volume
81,392
Close
48.97quote price arrow up+1.66 (+3.51%)
Volume
911,514
52 week range
30.02 - 58.72

...

Loading . . .

KEY STATS

  • Open47.34
  • Day High49.37
  • Day Low47.13
  • Prev Close47.31
  • 52 Week High58.72
  • 52 Week High Date07/07/20
  • 52 Week Low30.02
  • 52 Week Low Date03/16/20
  • Market Cap7.785B
  • Shares Out158.98M
  • 10 Day Average Volume0.82M
  • Dividend-
  • Dividend Yield-
  • Beta1.22
  • 1 Year % Change25.24

RATIOS/PROFITABILITY

  • EPS (TTM)-1.79
  • P/E (TTM)-27.35
  • Fwd P/E (NTM)-27.46
  • EBITDA (MRQ)-283.609M
  • ROE (MRQ)-42.47%
  • Revenue (MRQ)441.76M
  • Gross Margin (MRQ)95.35%
  • Net Margin (MRQ)-63.74%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date05/05/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest ACADIA Pharmaceuticals Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
ACADIA Pharmaceuticals Inc. (ACADIA) is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines to address the medical needs in central nervous system disorders. The Company's lead product, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA’s developments are focused on pimavanserin for additional neuropsychiatric conditions, trofinetide for...
Stephen Biggar M.D. Ph.D.
Chairman
Stephen Davis CPA
Chief Executive Officer
Srdjan Stankovic M.D.
President
Elena Ridloff
Chief Financial Officer
Austin Kim
Executive Vice President
Address
3611 Valley Centre Dr Ste 300
San Diego, CA
92130-3331
United States